This was the stock's second consecutive day of losses.

The stock's fall snapped a three-day winning streak.

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Apart from Eylea, profits from asthma drug Dupixent’s sales are a primary growth driver for REGN. Regeneron has a collaboration agreement with Sanofi for drugs like Dupixent and Kevzara.

The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine ...

The expected growth in Dupixent’s revenue, particularly with its strong launch in COPD, provides a solid foundation for Regeneron’s future financial performance. Additionally, the company is ...

Analysts note that the possibility of Amgen launching Pavblu at risk is seen as low due to potential substantial damages if Regeneron's patent is upheld. Dupixent continues to be a significant growth ...

Analysts note that the possibility of Amgen launching Pavblu at risk is seen as low due to potential substantial damages if Regeneron's patent is upheld. Dupixent continues to be a significant ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...